Vaginal microbial shifts are unaffected by oral pre-exposure prophylaxis in South African women

Sci Rep. 2022 Sep 28;12(1):16187. doi: 10.1038/s41598-022-20486-z.

Abstract

Vaginal microbiota have been shown to be a modifier of protection offered by topical tenofovir in preventing HIV infection in women, an effect not observed with oral tenofovir-based pre-exposure prophylaxis (PrEP). It remains unclear whether PrEP can influence the vaginal microbiota composition. This study investigated the impact of daily oral tenofovir disoproxil fumarate in combination with emtricitabine for PrEP on the vaginal microbiota in South African women. At baseline, Lactobacillus iners or Gardnerella vaginalis dominant vaginal communities were observed in the majority of participants. In cross sectional analysis, vaginal microbiota were not affected by the initiation and use of PrEP. Longitudinal analysis revealed that Lactobacillus crispatus-dominant "cervicotypes 1 (CT1)" communities had high probability of remaining stable in PrEP group, but had a higher probability of transitioning to L. iners-dominant CT2 communities in non-PrEP group. L. iners-dominant communities were more likely to transition to communities associated with bacterial vaginosis (BV), irrespective of PrEP or antibiotic use. As expected, BV-linked CTs had a higher probability of transitioning to L. iners than L. crispatus dominant CTs and this shift was not associated with PrEP use.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents
  • Cross-Sectional Studies
  • Emtricitabine
  • Female
  • HIV Infections* / complications
  • HIV Infections* / prevention & control
  • Humans
  • Pre-Exposure Prophylaxis*
  • South Africa
  • Tenofovir / therapeutic use
  • Vagina / microbiology
  • Vaginosis, Bacterial* / microbiology

Substances

  • Anti-Bacterial Agents
  • Tenofovir
  • Emtricitabine